%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2016-08-08T14:53:23-04:00
2016-08-08T14:53:25-04:00
2016-08-08T14:53:25-04:00
Adobe InDesign CC 2015 (Windows)
uuid:c76ed0e1-bcb5-4cdd-9d9f-d6865c4b77de
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
xmp.id:980ac24a-617e-e64a-847f-95238e6bd234
proof:pdf
xmp.iid:01e4cccf-bcb5-004c-b13f-0c880ec10ed8
xmp.did:a670d67f-26ad-d745-a58e-6e0959f13d67
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 2015 (Windows)
/
2016-08-08T14:53:23-04:00
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
3 0 obj
<>
endobj
5 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
6 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/Properties<>/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
16 0 obj
<>stream
BT
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
7 0 0 7 60.48 22.6817 Tm
(2 )Tj
/Span<>> BDC
( )Tj
EMC
59.297 0 Td
[(Pharmacology W)54.6 (atch)]TJ
4.081 0 0 4.081 535.1605 25.0127 Tm
(\256)Tj
ET
q
0 g
/GS1 gs
0 TL/Fm0 Do
Q
BT
/T1_0 1 Tf
-0.01 Tc 7 0 0 7 40.75 257.75 Tm
(PHARMACOLOGY WATCH)Tj
/T1_1 1 Tf
6 0 0 6 127.892 257.75 Tm
[(\231 is published monthly by AHC Media, LLC. Copyright \251)-10 ( )]TJ
-14.524 -1.167 Td
[(2016 AHC Media, LLC.)-10 ( )]TJ
/T1_2 1 Tf
0.01 Tw 8 0 0 8 40.75 240.75 Tm
(Author)Tj
/T1_1 1 Tf
(: )Tj
/T1_3 1 Tf
0 Tw 3.698 0 Td
(William T. Elliott, MD, FACP, )Tj
/T1_1 1 Tf
[(Medical Director, Pharmacy,)-9.9 ( )]TJ
-3.698 -1.25 Td
[(Northern California Kaiser Permanente Assistant Clinical Professor of)-9.9 ( )]TJ
0 -1.25 TD
(Medicine, University of California, San Francisco)Tj
/T1_2 1 Tf
T*
(Executive Editor:)Tj
/T1_1 1 Tf
( Leslie Coplin)Tj
/T1_2 1 Tf
T*
(Associate Managing Editor:)Tj
/T1_1 1 Tf
( Jonathan Springston)Tj
6 0 0 6 40.75 189.25 Tm
[(This is an educational publication designed to present scientific inform\
ation and opinion to)-10 ( )]TJ
0 -1.167 TD
[(health professionals, stimulate thought, and further investigation. It d\
oes not provide advice)-10 ( )]TJ
0 -1.167 TD
[(regarding medical diagnosis or treatment for any individual case. It is \
not intended for the)-10 ( )]TJ
0.01 Tw 0 -1.167 TD
(layman.)Tj
0.01 Tc 0 Tw 0 -1.917 TD
(STATEMENT OF FINANCIAL DISCLOSURE)Tj
-0.01 Tc 0 -1.167 TD
[(To reveal any potential bias in this publication, and in accordance with\
Accreditation Council)-9.9 ( )]TJ
0 -1.167 TD
[(for Continuing Medical Education guidelines, Dr. Elliott \(author\), Ms.\
Coplin \(executive)-10 ( )]TJ
T*
[(editor\), and Mr. Springston \(associate managing editor\) report no fin\
ancial relationships)-10 ( )]TJ
0 -1.167 TD
(relevant to this field of study.)Tj
ET
/CS0 CS 1 SCN
0.25 w 4 M
/GS1 gs
36.125 45.125 251.75 222.5 re
S
/CS0 cs 0.1 scn
122.4 50.76 160.85 69.12 re
f
0.86 0.57 0 0.16 K
0.3 w 10 M
q 1 0 0 1 151.4756 83.3042 cm
0 0 m
42.017 0 l
S
Q
BT
0 0 0 1 k
/GS0 gs
/T1_2 1 Tf
0.05 Tc 8 0 0 8 126.9 108.1801 Tm
[(SUBSCRIBER INFORMA)92 (TION)]TJ
-0.01 Tc 7 0 0 7 126.9 97.9041 Tm
(Customer Service: \(800\) 688-2421)Tj
/T1_1 1 Tf
6 0 0 6 126.9 90.9041 Tm
(Email Address: Jonathan.Springston@AHCMedia.com)Tj
0.01 Tw 0 -1.167 TD
(Website: )Tj
0.86 0.57 0 0.16 k
/GS1 gs
4.096 0 Td
(AHCMedia.com)Tj
0 0 0 1 k
/GS0 gs
0 Tw -4.096 -1.917 Td
[(Address Correspondence to: AHC Media, One Atlanta)-10 ( )]TJ
T*
[(Plaza, 950 East Paces Ferry Road NE, Suite 2850, Atlanta,)-9.9 ( )]TJ
T*
[(GA 30326.)-10 ( )]TJ
ET
/PlacedGraphic /MC0 BDC
EMC
q
44.685 73.418 70.72 32.443 re
W n
/GS1 gs
q 1 0 0 1 52.0285 92.6745 cm
0 0 m
-0.027 0 l
-0.163 -0.531 -0.313 -1.171 -0.463 -1.715 c
-1.171 -3.975 l
1.184 -3.975 l
0.463 -1.715 l
0.286 -1.157 0.136 -0.531 0 0 c
f
Q
q 1 0 0 1 70.4899 86.0851 cm
0 0 m
0.667 0 1.375 0.136 1.824 0.327 c
2.097 -0.994 l
1.702 -1.184 0.831 -1.402 -0.286 -1.402 c
-3.199 -1.402 -4.969 0.422 -4.969 3.227 c
-4.969 6.249 -2.859 8.073 -0.054 8.073 c
1.048 8.073 1.824 7.842 2.165 7.665 c
1.811 6.331 l
1.375 6.521 0.762 6.685 0.014 6.685 c
-1.852 6.685 -3.199 5.514 -3.199 3.308 c
-3.199 1.28 -2.028 0 0 0 c
-6.127 -1.252 m
-7.801 -1.252 l
-7.801 2.791 l
-11.681 2.791 l
-11.681 -1.252 l
-13.356 -1.252 l
-13.356 7.924 l
-11.681 7.924 l
-11.681 4.248 l
-7.801 4.248 l
-7.801 7.924 l
-6.127 7.924 l
h
-16.174 -1.252 m
-17.005 1.348 l
-19.905 1.348 l
-20.694 -1.252 l
-22.423 -1.252 l
-19.483 7.924 l
-17.345 7.924 l
-14.364 -1.252 l
h
-25.805 -12.253 31.616 31.616 re
-25.805 19.363 m
f
Q
q 1 0 0 1 88.2162 88.5766 cm
0 0 m
-0.054 1.185 -0.123 2.614 -0.109 3.853 c
-0.15 3.853 l
-0.449 2.736 -0.831 1.498 -1.239 0.34 c
-2.587 -3.635 l
-3.866 -3.635 l
-5.092 0.286 l
-5.446 1.457 -5.772 2.709 -6.018 3.853 c
-6.045 3.853 l
-6.086 2.655 -6.14 1.198 -6.208 -0.055 c
-6.413 -3.744 l
-7.978 -3.744 l
-7.365 5.432 l
-5.16 5.432 l
-3.962 1.743 l
-3.635 0.667 -3.349 -0.422 -3.118 -1.443 c
-3.077 -1.443 l
-2.832 -0.449 -2.519 0.681 -2.165 1.756 c
-0.899 5.432 l
1.28 5.432 l
1.811 -3.744 l
0.177 -3.744 l
h
f
Q
q 1 0 0 1 95.8269 88.8489 cm
0 0 m
0.014 0.613 -0.259 1.62 -1.375 1.62 c
-2.41 1.62 -2.846 0.681 -2.914 0 c
h
-2.914 -1.171 m
-2.873 -2.369 -1.947 -2.886 -0.871 -2.886 c
-0.095 -2.886 0.449 -2.764 0.966 -2.587 c
1.211 -3.73 l
0.64 -3.975 -0.15 -4.152 -1.103 -4.152 c
-3.254 -4.152 -4.52 -2.832 -4.52 -0.803 c
-4.52 1.035 -3.404 2.764 -1.28 2.764 c
0.871 2.764 1.579 0.994 1.579 -0.463 c
1.579 -0.776 1.552 -1.021 1.525 -1.171 c
h
f
Q
q 1 0 0 1 103.1923 88.6991 cm
0 0 m
0 0.136 -0.014 0.313 -0.041 0.449 c
-0.191 1.089 -0.721 1.62 -1.484 1.62 c
-2.559 1.62 -3.158 0.667 -3.158 -0.558 c
-3.158 -1.783 -2.559 -2.668 -1.497 -2.668 c
-0.817 -2.668 -0.218 -2.205 -0.054 -1.484 c
-0.014 -1.334 0 -1.171 0 -0.994 c
h
1.675 5.8 m
1.675 -2.001 l
1.675 -2.682 1.702 -3.417 1.729 -3.866 c
0.245 -3.866 l
0.163 -2.818 l
0.136 -2.818 l
-0.259 -3.553 -1.062 -4.016 -2.015 -4.016 c
-3.608 -4.016 -4.86 -2.668 -4.86 -0.626 c
-4.874 1.593 -3.485 2.914 -1.892 2.914 c
-0.98 2.914 -0.327 2.546 -0.027 2.056 c
0 2.056 l
0 5.8 l
h
f
Q
106.664 91.463 1.675 -6.63 re
106.664 84.833 m
108.448 93.314 m
108.448 92.824 108.08 92.416 107.495 92.416 c
106.936 92.416 106.569 92.824 106.569 93.314 c
106.569 93.832 106.95 94.227 107.508 94.227 c
108.08 94.227 108.434 93.832 108.448 93.314 c
f
q 1 0 0 1 113.6622 88.0729 cm
0 0 m
-1.184 0.014 -2.315 -0.231 -2.315 -1.239 c
-2.315 -1.892 -1.892 -2.192 -1.361 -2.192 c
-0.681 -2.192 -0.204 -1.756 -0.041 -1.28 c
0 -1.157 0 -1.035 0 -0.912 c
h
1.634 -1.647 m
1.634 -2.246 1.661 -2.832 1.743 -3.24 c
0.231 -3.24 l
0.109 -2.505 l
0.068 -2.505 l
-0.327 -3.022 -1.021 -3.39 -1.892 -3.39 c
-3.226 -3.39 -3.975 -2.423 -3.975 -1.416 c
-3.975 0.245 -2.492 1.103 -0.041 1.089 c
-0.041 1.198 l
-0.041 1.634 -0.218 2.355 -1.389 2.355 c
-2.042 2.355 -2.723 2.151 -3.172 1.865 c
-3.499 2.954 l
-3.009 3.254 -2.151 3.54 -1.103 3.54 c
1.021 3.54 1.634 2.192 1.634 0.735 c
h
f
Q
Q
BT
/T1_4 1 Tf
0.01 Tc 10 0 0 10 36 736.2775 Tm
(possible. \()Tj
/T1_5 1 Tf
-0.01 Tw (Circulation)Tj
/T1_4 1 Tf
0 Tw ( 2016;134:00\22600. doi: 10.1161/)Tj
-0.01 Tw 0 -1.2 TD
(CIR.0000000000000426\).)Tj
/TT0 1 Tf
0 Tc 0 Tw 14 0 0 14 36 696.2775 Tm
[(Study: Knee R)18.7 (eplacement Can Lead )]TJ
14.635 0 Td
( )Tj
-14.635 -1.143 Td
(to Chronic Opioid Use)Tj
/T1_4 1 Tf
0.01 Tc 10 0 0 10 36 668.2775 Tm
[(T)98 (otal knee replacement is the surgical procedure most)10 ( )]TJ
T*
(commonly associated with chronic opioid use in opioid-)Tj
T*
[(na\357ve patients, according to a new study)92 (.)]TJ
0 -2.4 TD
[(In a retrospective analysis, researchers from Stanford)10 ( )]TJ
0 -1.2 TD
(compared the records of more than 640,000 opioid-)Tj
T*
(na\357ve surgical patients to more than 18 million opioid-)Tj
T*
[(na\357ve non-surgical patients. Researchers reviewed 11)10 ( )]TJ
T*
[(surgical procedures, including knee and hip arthroplasty)92 (,)10 ( )]TJ
T*
(laparoscopic and open cholecystectomies, appendecto)Tj
0 Tc (-)Tj
0.01 Tc T*
[(mies, C-sections, sinus surgery)92 (, cataract surgery)92 (, trans)]TJ
0 Tc (-)Tj
0.01 Tc T*
[(urethral resections of the prostate \(TURP\), and simple)10 ( )]TJ
-0.01 Tw T*
[(mastectomies.)10 ( )]TJ
0 Tw 0 -2.4 TD
[(Chronic opioid use was de\037ned as \037lling 10 or more)10 ( )]TJ
0 -1.2 TD
[(prescriptions or more than 120 days\222 supply of an)10 ( )]TJ
T*
[(opioid in the \037rst year after surgery)92 (, excluding the \037rst)10 ( )]TJ
T*
[(90 postoperative days. Cataract surgery)91.9 (, sinus surgery)92 (,)10 ( )]TJ
T*
[(laparoscopic appendectomy)92 (, and TURP were not as)]TJ
0 Tc (-)Tj
0.01 Tc T*
[(sociated with chronic opioid use. For other procedures,)10 ( )]TJ
T*
(C-sections had the lowest risk, while total knee replace)Tj
0 Tc (-)Tj
0.01 Tc T*
[(ment had the highest risk \(1.41%; 95% con\037dence)10 ( )]TJ
T*
[(interval, 1.29%-1.53%\). Men and elderly patients were)10 ( )]TJ
T*
(at the highest risk for chronic opioid use \()Tj
/T1_5 1 Tf
[(JAMA Intern)9.9 ( )]TJ
-0.01 Tw T*
(Med)Tj
/T1_4 1 Tf
0 Tw ( Published online July 11, 2016. doi:10.1001/ja)Tj
0 Tc (-)Tj
0.01 Tc -0.01 Tw T*
(mainternmed.2016.3298\).)Tj
/TT0 1 Tf
0 Tc 0 Tw 14 0 0 14 36 340.2775 Tm
[(FD)17.4 (A Actions)]TJ
/T1_4 1 Tf
0.01 Tc 10 0 0 10 36 328.2775 Tm
[(Just in time for \036u season, the FDA has approved the)10 ( )]TJ
T*
[(\037rst generic oseltamivir \(T)86 (ami\036u\) to treat and prevent)10 ( )]TJ
T*
(in\036uenza. The drug is indicated for patients )Tj
/T1_6 1 Tf
0 Tc (\037)Tj
/T1_4 1 Tf
0.01 Tc 20.099 0 Td
[( 2 weeks of)10 ( )]TJ
-20.099 -1.2 Td
[(age who have suffered from \036u symptoms for no more)10.1 ( )]TJ
T*
(than 48 hours and for prevention of the \036u in patients )Tj
/T1_6 1 Tf
0 Tc (\037)Tj
/T1_4 1 Tf
( )Tj
0.01 Tc 27 45.6 Td
[(1 year of age. Natco Pharma and its U.S. partner)111 (, Alvo)]TJ
0 Tc (-)Tj
0.01 Tc T*
[(gen, have the \037rst generic approval and will be the only)10 ( )]TJ
T*
(generic supplier for six months under a patent agree)Tj
0 Tc (-)Tj
0.01 Tc T*
[(ment with Roche Pharmaceuticals, the manufacturer of)10 ( )]TJ
-0.01 Tw T*
[(T)86 (ami\036u.)]TJ
0 Tw 0 -2.4 TD
[(AstraZeneca has lost a last-ditch effort to protect its)10 ( )]TJ
0 -1.2 TD
[(blockbuster statin rosuvastatin \(Crestor\) from generic)10 ( )]TJ
T*
[(competition. The company argued before a federal court)10 ( )]TJ
T*
[(that the drug had recently been approved under the)10 ( )]TJ
T*
(Orphan Drug Act to treat children with homozygous fa)Tj
0 Tc (-)Tj
0.01 Tc T*
(milial hypercholesterolemia, a rare condition. AstraZen)Tj
0 Tc (-)Tj
0.01 Tc T*
[(eca lost the case and was criticized for attempted abuse)10 ( )]TJ
T*
(of the Orphan Drug Act, according to )Tj
/T1_5 1 Tf
[(The New Y)74 (ork)10 ( )]TJ
-0.01 Tw T*
[(T)37 (imes)]TJ
/T1_4 1 Tf
0 Tw [(. Subsequently)92 (, the FDA approved several more ge)]TJ
0 Tc (-)Tj
0.01 Tc T*
[(neric versions of rosuvastatin in early August. The drug\222)74 (s)10 ( )]TJ
T*
[(\037rst generic copy was approved in May)92 (.)]TJ
0 -2.4 TD
[(The FDA has approved the \037fth GLP-1 agonist to treat)10 ( )]TJ
0 -1.2 TD
[(type 2 diabetes. Lixisenatide is a once-daily injection)10 ( )]TJ
T*
[(used to improve glycemic control along with diet and)10 ( )]TJ
T*
[(exercise in type 2 diabetics. The drug previously was)10 ( )]TJ
T*
[(approved in Europe in 2013. It is not indicated for type)10 ( )]TJ
T*
[(1 diabetes or diabetic ketoacidosis. The approval was)10 ( )]TJ
T*
[(based on 10 clinical trials consisting of 5,400 patients)9.9 ( )]TJ
T*
[(presenting with type 2 diabetes in which the drug was)10 ( )]TJ
T*
[(evaluated as a standalone therapy and in combination)10 ( )]TJ
T*
[(with metformin, sulfonylureas, pioglitazone, and basal)10 ( )]TJ
T*
[(insulin. Lixisenatide improved A1c levels in these trials.)10 ( )]TJ
T*
(In 6,000 patients at risk for cardiovascular disease, lix)Tj
0 Tc (-)Tj
0.01 Tc T*
(isenatide did not increase the risk of adverse events.)Tj
0 -2.4 TD
[(The FDA has approved li\037tegrast ophthalmic solution)10 ( )]TJ
0 -1.2 TD
[(for the treatment of dry eye disease. The drug is the \037rst)10 ( )]TJ
T*
[(of a new class of lymphocyte function-associated antigen)10 ( )]TJ
T*
[(1\(LF)55 (A-1\) antagonists. Safety and ef\037cacy was shown in)10 ( )]TJ
T*
[(four studies of more than 1,000 patients \(76% female\))10 ( )]TJ
T*
[(age 19-97 years. Patients were randomized to li\037tegrast)10 ( )]TJ
T*
(or placebo twice a day for 12 weeks. Li\037tegrast re)Tj
0 Tc (-)Tj
0.01 Tc T*
[(sulted in more improvements in both the signs and the)10 ( )]TJ
T*
[(symptoms of eye dryness than the groups treated with)9.9 ( )]TJ
T*
[(placebo. Li\037tegrast ophthalmic solution is marketed as)10 ( )]TJ
T*
[(Xiidra. It is expected to be priced at $426 for a 30-day)10 ( )]TJ
-0.01 Tw T*
[(supply)92 (.)]TJ
0 Tw 0 -2.4 TD
[(The FDA has approved adapalene gel 0.1% \(Differin)10 ( )]TJ
0 -1.2 TD
(Gel\) for OTC use for the treatment of acne in those )Tj
/T1_6 1 Tf
0 Tc (\037)Tj
/T1_4 1 Tf
0.01 Tw 23.608 0 Td
[( 1)-10 (2 )]TJ
0.01 Tc 0 Tw -23.608 -1.2 Td
(years of age. It represents the \037rst retinoid to be avail)Tj
0 Tc (-)Tj
0.01 Tc T*
[(able OTC and is the \037rst new active ingredient for acne)10 ( )]TJ
T*
(available OTC in nearly 30 years. The drug was origi)Tj
0 Tc (-)Tj
0.01 Tc T*
[(nally approved in 1996. Five postmarking trials have)10 ( )]TJ
T*
[(proven safety and ef\037cacy since 1996, also showing that)10 ( )]TJ
T*
[(consumers can understand the OTC labeling and use the)10 ( )]TJ
T*
[(product appropriately)91.9 (. Adapalene gel 0.1% OTC will be)10 ( )]TJ
T*
[(marketed as Differin Gel 0.1%. )40 ( )]TJ
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
0 Tc 14.408 0 Td
<0084>Tj
ET
endstream
endobj
24 0 obj
<>>>/Subtype/Form>>stream
0 0 0 1 K
3 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 18 754.5 cm
0 0 m
558 0 l
S
Q
endstream
endobj
10 0 obj
<>
endobj
23 0 obj
<>
endobj
25 0 obj
<>stream
application/postscript
AHCmedia(New)_3 tag options_11.8.13
Travis
2014-09-09T14:01:27-04:00
2014-09-09T14:01:27-04:00
2014-09-09T14:01:27-04:00
Adobe Illustrator CC 2014 (Windows)
xmp.iid:bdec626a-762d-6946-8d41-56d8de9e49a7
xmp.did:bdec626a-762d-6946-8d41-56d8de9e49a7
uuid:5D20892493BFDB11914A8590D31508C8
proof:pdf
xmp.iid:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
xmp.did:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
uuid:5D20892493BFDB11914A8590D31508C8
proof:pdf
converted
from application/pdf to <unknown>
saved
xmp.iid:D27F11740720681191099C3B601C4548
2008-04-17T14:19:15+05:30
Adobe Illustrator CS4
/
converted
from application/pdf to <unknown>
converted
from application/pdf to <unknown>
saved
xmp.iid:F97F1174072068118D4ED246B3ADB1C6
2008-05-15T16:23:06-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FA7F1174072068118D4ED246B3ADB1C6
2008-05-15T17:10:45-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:EF7F117407206811A46CA4519D24356B
2008-05-15T22:53:33-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F07F117407206811A46CA4519D24356B
2008-05-15T23:07:07-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811BDDDFD38D0CF24DD
2008-05-16T10:35:43-07:00
Adobe Illustrator CS4
/
converted
from application/pdf to <unknown>
saved
xmp.iid:F97F117407206811BDDDFD38D0CF24DD
2008-05-16T10:40:59-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to <unknown>
saved
xmp.iid:FA7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:26:55-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FB7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:29:01-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FC7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:29:20-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FD7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:30:54-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FE7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:31:22-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B233668C16206811BDDDFD38D0CF24DD
2008-05-16T12:23:46-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B333668C16206811BDDDFD38D0CF24DD
2008-05-16T13:27:54-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B433668C16206811BDDDFD38D0CF24DD
2008-05-16T13:46:13-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F11740720681197C1BF14D1759E83
2008-05-16T15:47:57-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F87F11740720681197C1BF14D1759E83
2008-05-16T15:51:06-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F97F11740720681197C1BF14D1759E83
2008-05-16T15:52:22-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:FA7F117407206811B628E3BF27C8C41B
2008-05-22T13:28:01-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:FF7F117407206811B628E3BF27C8C41B
2008-05-22T16:23:53-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:07C3BD25102DDD1181B594070CEB88D9
2008-05-28T16:45:26-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:F87F1174072068119098B097FDA39BEF
2008-06-02T13:25:25-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811BB1DBF8F242B6F84
2008-06-09T14:58:36-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F97F117407206811ACAFB8DA80854E76
2008-06-11T14:31:27-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:0180117407206811834383CD3A8D2303
2008-06-11T22:37:35-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811818C85DF6A1A75C3
2008-06-27T14:40:42-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:2759AC6B4FA8E211B099CEB363CBA397
2013-04-18T13:43:03-04:00
Adobe Illustrator CS4
/
saved
xmp.iid:5E11DEB5A8216811822A8C4A5BB13D00
2014-01-03T17:39:31-05:00
Adobe Illustrator CS6 (Macintosh)
/
converted
from application/postscript to application/vnd.adobe.illustrator
saved
xmp.iid:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
2014-01-06T10:41:10-05:00
Adobe Illustrator CC (Windows)
/
converted
from application/postscript to application/vnd.adobe.illustrator
saved
xmp.iid:bdec626a-762d-6946-8d41-56d8de9e49a7
2014-09-09T14:01:27-04:00
Adobe Illustrator CC 2014 (Windows)
/
Print
False
False
1
3.584901
1.584901
Inches
Black
Default Swatch Group
0
White
CMYK
PROCESS
0.000000
0.000000
0.000000
0.000000
Black
CMYK
PROCESS
0.000000
0.000000
0.000000
100.000000
CMYK Red
CMYK
PROCESS
0.000000
100.000000
100.000000
0.000000
CMYK Yellow
CMYK
PROCESS
0.000000
0.000000
100.000000
0.000000
CMYK Green
CMYK
PROCESS
100.000000
0.000000
100.000000
0.000000
CMYK Cyan
CMYK
PROCESS
100.000000
0.000000
0.000000
0.000000
CMYK Blue
CMYK
PROCESS
100.000000
100.000000
0.000000
0.000000
CMYK Magenta
CMYK
PROCESS
0.000000
100.000000
0.000000
0.000000
C=15 M=100 Y=90 K=10
CMYK
PROCESS
15.000000
100.000000
90.000000
10.000000
C=0 M=90 Y=85 K=0
CMYK
PROCESS
0.000000
90.000000
85.000000
0.000000
C=0 M=80 Y=95 K=0
CMYK
PROCESS
0.000000
80.000000
95.000000
0.000000
C=0 M=50 Y=100 K=0
CMYK
PROCESS
0.000000
50.000000
100.000000
0.000000
C=0 M=35 Y=85 K=0
CMYK
PROCESS
0.000000
35.000000
85.000000
0.000000
C=5 M=0 Y=90 K=0
CMYK
PROCESS
5.000000
0.000000
90.000000
0.000000
C=20 M=0 Y=100 K=0
CMYK
PROCESS
20.000000
0.000000
100.000000
0.000000
C=50 M=0 Y=100 K=0
CMYK
PROCESS
50.000000
0.000000
100.000000
0.000000
C=75 M=0 Y=100 K=0
CMYK
PROCESS
75.000000
0.000000
100.000000
0.000000
C=85 M=10 Y=100 K=10
CMYK
PROCESS
85.000000
10.000000
100.000000
10.000000
C=90 M=30 Y=95 K=30
CMYK
PROCESS
90.000000
30.000000
95.000000
30.000000
C=75 M=0 Y=75 K=0
CMYK
PROCESS
75.000000
0.000000
75.000000
0.000000
C=80 M=10 Y=45 K=0
CMYK
PROCESS
80.000000
10.000000
45.000000
0.000000
C=70 M=15 Y=0 K=0
CMYK
PROCESS
70.000000
15.000000
0.000000
0.000000
C=85 M=50 Y=0 K=0
CMYK
PROCESS
85.000000
50.000000
0.000000
0.000000
C=100 M=95 Y=5 K=0
CMYK
PROCESS
100.000000
95.000000
5.000000
0.000000
C=100 M=100 Y=25 K=25
CMYK
PROCESS
100.000000
100.000000
25.000000
25.000000
C=75 M=100 Y=0 K=0
CMYK
PROCESS
75.000000
100.000000
0.000000
0.000000
C=50 M=100 Y=0 K=0
CMYK
PROCESS
50.000000
100.000000
0.000000
0.000000
C=35 M=100 Y=35 K=10
CMYK
PROCESS
35.000000
100.000000
35.000000
10.000000
C=10 M=100 Y=50 K=0
CMYK
PROCESS
10.000000
100.000000
50.000000
0.000000
C=0 M=95 Y=20 K=0
CMYK
PROCESS
0.000000
95.000000
20.000000
0.000000
C=25 M=25 Y=40 K=0
CMYK
PROCESS
25.000000
25.000000
40.000000
0.000000
C=40 M=45 Y=50 K=5
CMYK
PROCESS
40.000000
45.000000
50.000000
5.000000
C=50 M=50 Y=60 K=25
CMYK
PROCESS
50.000000
50.000000
60.000000
25.000000
C=55 M=60 Y=65 K=40
CMYK
PROCESS
55.000000
60.000000
65.000000
40.000000
C=25 M=40 Y=65 K=0
CMYK
PROCESS
25.000000
40.000000
65.000000
0.000000
C=30 M=50 Y=75 K=10
CMYK
PROCESS
30.000000
50.000000
75.000000
10.000000
C=35 M=60 Y=80 K=25
CMYK
PROCESS
35.000000
60.000000
80.000000
25.000000
C=40 M=65 Y=90 K=35
CMYK
PROCESS
40.000000
65.000000
90.000000
35.000000
C=40 M=70 Y=100 K=50
CMYK
PROCESS
40.000000
70.000000
100.000000
50.000000
C=50 M=70 Y=80 K=70
CMYK
PROCESS
50.000000
70.000000
80.000000
70.000000
PANTONE 288 U
SPOT
100.000000
CMYK
100.000000
67.000002
0.000000
23.000000
PANTONE 313 C
SPOT
100.000000
CMYK
100.000000
0.000000
8.000200
13.000500
PANTONE 313 U
SPOT
100.000000
CMYK
100.000000
0.000000
8.000000
13.000000
PANTONE 187 U
SPOT
100.000000
CMYK
0.000000
100.000000
78.999299
19.999699
PANTONE 309 U
SPOT
100.000000
CMYK
100.000000
0.000000
8.999600
72.000098
Grays
1
C=0 M=0 Y=0 K=100
CMYK
PROCESS
0.000000
0.000000
0.000000
100.000000
C=0 M=0 Y=0 K=90
CMYK
PROCESS
0.000000
0.000000
0.000000
89.999400
C=0 M=0 Y=0 K=80
CMYK
PROCESS
0.000000
0.000000
0.000000
79.998800
C=0 M=0 Y=0 K=70
CMYK
PROCESS
0.000000
0.000000
0.000000
69.999700
C=0 M=0 Y=0 K=60
CMYK
PROCESS
0.000000
0.000000
0.000000
59.999100
C=0 M=0 Y=0 K=50
CMYK
PROCESS
0.000000
0.000000
0.000000
50.000000
C=0 M=0 Y=0 K=40
CMYK
PROCESS
0.000000
0.000000
0.000000
39.999400
C=0 M=0 Y=0 K=30
CMYK
PROCESS
0.000000
0.000000
0.000000
29.998800
C=0 M=0 Y=0 K=20
CMYK
PROCESS
0.000000
0.000000
0.000000
19.999700
C=0 M=0 Y=0 K=10
CMYK
PROCESS
0.000000
0.000000
0.000000
9.999100
C=0 M=0 Y=0 K=5
CMYK
PROCESS
0.000000
0.000000
0.000000
4.998800
Brights
1
C=0 M=100 Y=100 K=0
CMYK
PROCESS
0.000000
100.000000
100.000000
0.000000
C=0 M=75 Y=100 K=0
CMYK
PROCESS
0.000000
75.000000
100.000000
0.000000
C=0 M=10 Y=95 K=0
CMYK
PROCESS
0.000000
10.000000
95.000000
0.000000
C=85 M=10 Y=100 K=0
CMYK
PROCESS
85.000000
10.000000
100.000000
0.000000
C=100 M=90 Y=0 K=0
CMYK
PROCESS
100.000000
90.000000
0.000000
0.000000
C=60 M=90 Y=0 K=0
CMYK
PROCESS
60.000000
90.000000
0.003100
0.003100
Adobe PDF library 10.01
endstream
endobj
17 0 obj
<>
endobj
18 0 obj
<>
endobj
19 0 obj
<>
endobj
20 0 obj
<>
endobj
21 0 obj
<>
endobj
11 0 obj
<>
endobj
22 0 obj
<>
endobj
12 0 obj
<>
endobj
13 0 obj
<>
endobj
44 0 obj
<>
endobj
45 0 obj
<>stream
HdNV{q)>J\> i\?m 6eȷ<O/fst]~x{_Nϯ7ww˛oxx2r/?2އp?D??yz{qfzOt:m-_7͆